Where Will Aldeyra Therapeutics Inc (ALDX) Stock Go Next After It Is Up 3.50% in a Week?

Overall market sentiment has been high on Aldeyra Therapeutics Inc (ALDX) stock lately. ALDX receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Aldeyra Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ALDX!

See Full ALDX Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With ALDX Stock Today?

Aldeyra Therapeutics Inc (ALDX) stock is lower by -10.34% while the S&P 500 has gained 0.3% as of 1:34 PM on Tuesday, Nov 2. ALDX has fallen -$0.95 from the previous closing price of $9.24 on volume of 1,313,049 shares. Over the past year the S&P 500 has risen 39.80% while ALDX has gained 26.95%. ALDX lost -$1.09 per share in the over the last 12 months.

More About Aldeyra Therapeutics Inc

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Click Here to get the full Stock Report for Aldeyra Therapeutics Inc stock.